罗格列酮联合二甲双胍治疗2型糖尿病临床疗效分析

Clinical observation of curative effect of rosiglitazone combined with metformin in type 2 diabetes

目的观察罗格列酮联合二甲双胍治疗2型糖尿病的临床效果。方法将65例符合2型糖尿病诊断标准的门诊患者随机分组,试验组35例,予以口服罗格列酮及二甲双胍联合治疗;对照组30例,仅予以口服罗格列酮治疗。观察两组患者治疗前及治疗12周后FBG、FINS、DBP、SBP和IRI变化情况,并监测患者肝肾功能和血常规。结果治疗后两组患者血糖、血压及胰岛素均较治疗前有显著下降(P<0.05);试验组FBG、FINS、DBP、SBP及IRI等指标下降幅度均大于对照组,差异有统计学意义(P<0.05);两组患者均无肝、肾功能损害。结论罗格列酮联合二甲双胍治疗2型糖尿病,具有改善患者胰岛素抵抗和降低血压的作用,且临床疗效确切,优于单独使用罗格列酮。

Objective To study the curative effect of rosiglitazone combined with metformin in the treatment of type 2 diabetes.Methods 65 outpatients were randomly divided into two groups.The tested group with 35 patients were treated with rosigilitazone and metformin,while the contrast group with 30 patients were treated with rosigilitazone solely.Observe all patients’ FBG、FINS、DBP、 SBP and IRI of before treatment and 12 weeks after treatment.Results The FBG、FINS and BP of two groups had been descend after treatment（P 0.05） .The descending extent of the tested group＇s FBG、FINS、DBP、SBP and IRI were higher than the contrast group,and there were statistically significant difference between the two groups（P 0.05） .There were no harm to liver and kidney of all patients.Conclusion Using rosiglitazone with metformin in the treatment of type 2 diabetes,can ameliorate IR and reduce BP of patients,and the curative effect is far better than that only with rosiglitazone.